Evidence map›Paper›PMID 27426251›Full record

ArticleScientific reports2016

Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility.

Anne-Kathrin Brunnemann, Kristin Liermann, Stefanie Deinhardt-Emmer, Gregor Maschkowitz, Anja Pohlmann, Beate Sodeik, Helmut Fickenscher, Andreas Sauerbrei, Andi Krumbholz

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Anne-Kathrin BrunnemannInstitute of Infection Medicine, Christian-Albrecht University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Kristin LiermannInstitute of Virology and Antiviral Therapy, Consulting Laboratory for HSV and VZV, Jena University Hospital, Jena, Germany.
Stefanie Deinhardt-EmmerInstitute of Medical Microbiology, Jena University Hospital, Jena, Germany.
Gregor MaschkowitzInstitute of Infection Medicine, Christian-Albrecht University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Anja PohlmannInstitute of Virology, Hannover Medical School, Hannover, Germany.
Beate SodeikInstitute of Virology, Hannover Medical School, Hannover, Germany.
Helmut FickenscherInstitute of Infection Medicine, Christian-Albrecht University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Andreas SauerbreiInstitute of Virology and Antiviral Therapy, Consulting Laboratory for HSV and VZV, Jena University Hospital, Jena, Germany.
Andi KrumbholzInstitute of Infection Medicine, Christian-Albrecht University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Christian-Albrechts-Universität zu Kiel · DEJena University Hospital · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we describe a novel reliable method to assess the significance of individual mutations within the thymidine kinase (TK) gene of herpes simplex virus type 1 (HSV-1) to nucleoside analogue resistance. Eleven defined single nucleotide polymorphisms that occur in the TK gene of clinical HSV-1 isolates and a fluorescence reporter were introduced into the HSV-1 strain 17(+) that had been cloned into a bacterial artificial chromosome. The susceptibility of these different strains to aciclovir, penciclovir, brivudin, and foscarnet was determined with a modified cytopathic effect reduction assay. The strains were also tested for their aciclovir susceptibility by measuring the relative fluorescence intensity as an indicator for HSV-1 replication and by quantifying the virus yield. Our data indicate that the amino acid substitutions R41H, R106H, A118V, L139V, K219T, S276R, L298R, S345P, and V348I represent natural polymorphisms of the TK protein, whereas G61A and P84L mediate broad cross-resistance against aciclovir, penciclovir, brivudin, and susceptibility to foscarnet. This method allows the definition of the resistance genotype of otherwise unclear mutations in the TK gene of HSV-1. Thus, it provides a scientific basis for antiviral testing in clinical isolates of patients suffering from serious diseases and will facilitate testing of new antivirals against HSV-1.

Indexed as

AcyclovirAnimalsAntiviral AgentsChlorocebus aethiopsDrug Resistance, ViralHerpesvirus 1, HumanKineticsMutationPolymerase Chain ReactionRecombination, GeneticThymidine KinaseTransfectionVero CellsViral LoadVirus ReplicationAcyclovirAntiviral AgentsThymidine Kinase

Identifiers

PMID27426251
PMCPMC4947914
OpenAlexW2504945102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.